Pan-KRAS Inhibitor Daraxonrasib Shrinks Tumors in 30% of Metastatic Lung Cancer Patients

Precision oncologists have spent the last 15 years arguing that the future of cancer treatment lies in highly specific, narrow-spectrum drugs that target single genetic mutations to spare healthy tissue. Conversely, evolutionary biologists and a growing faction of cancer researchers maintain that tumors are too adaptable for sniper fire; they argue that because cancers rapidly mutate around narrow drugs, only broad-spectrum inhibitors that block entire families of proteins can prevent inevitable relapse.[6]

That philosophical divide is now being tested in human patients. On September 2, 2026, researchers at Memorial Sloan Kettering Cancer Center and UT MD Anderson Cancer Center published early-stage trial data for daraxonrasib, an experimental "pan-KRAS" inhibitor designed to block multiple mutations of the notorious RAS protein simultaneously.[1][2]

The results, published in the AACR Journals and presented to the medical community, showed that the drug shrank tumors in 30% of patients with heavily pretreated, metastatic non-small cell lung cancer (NSCLC). Lung cancer remains the leading cause of cancer mortality, accounting for roughly 1.8 million deaths globally each year, and patients in this trial had already exhausted standard chemotherapy and targeted treatments.[4]

Historically, the KRAS protein was considered "undruggable" because its smooth surface lacked obvious binding pockets for medications. While breakthroughs in 2021 yielded drugs like sotorasib that successfully target one specific mutation (KRAS G12C)—which accounts for about 13% of NSCLC cases—tumors frequently develop resistance by switching to a different KRAS mutation. Daraxonrasib attempts to bypass this escape route by inhibiting the entire RAS family of proteins.[3][6]

For patients reading these results, the 30% response rate requires careful interpretation. It means that nearly one-third of participants saw their tumors measurably decrease in size, which is a significant clinical signal in late-stage disease. However, it also means that 70% of patients did not experience tumor shrinkage, underscoring that pan-KRAS inhibition is not a universal cure.[5]

The broader the mechanism, the higher the risk of collateral damage. Blocking all RAS proteins can interfere with healthy cellular functions, raising concerns about toxicity. The trial data indicates an "encouraging signal" regarding safety across the initial dosing cohorts, but long-term side effects remain a critical question as the drug moves into larger Phase 2 and Phase 3 trials.[5][6]

While the preliminary releases from Memorial Sloan Kettering and MD Anderson did not provide direct quotations from the lead investigators, the institutional framing emphasized the "initial antitumor activity" as a proof-of-concept for the pan-KRAS approach. The drug was originally developed with pancreatic cancer in mind—where KRAS mutations are present in over 90% of tumors—making its efficacy in lung cancer a notable expansion of its potential utility.[1][2][3]

The next verifiable checkpoint will be the release of progression-free survival (PFS) data at upcoming oncology conferences in late 2026 or early 2027. Those figures will reveal not just how many tumors shrank, but how long that shrinkage lasted before the cancer adapted again. Until those duration metrics are published, daraxonrasib remains a promising experimental tool rather than an immediate clinical reality.[6]